Drugs / Neo-Kidney Augment
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02008851 | Dec 2013 → Dec 2014 | chronic kidney disease | Tengion | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT02525263 | Jul 2016 → May 2017 | chronic kidney disease, type 2 diabetes mellitus | Prokidney | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neo-Kidney Augment | “Biological: Neo-kidney augment” NCT02008851 ↗ |
| Known as | NKA | “Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)” NCT02525263 ↗ |
| Modality | Cell therapy | “selected renal cells” NCT02008851 ↗ |
| Route | Other | “all NKA injections are to be given into the kidney that was biopsied.” NCT02525263 ↗ |